SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is surging above $71,000, igniting community excitement and signaling a potential end to recent downtrends as many anticipate a new bull phase and the liquidation of short positions. The rally is supported by ongoing conversations around proposed crypto legislation, with prominent figures criticizing banks for hindering market progress, and some investors increasingly viewing Bitcoin as a resilient asset amidst global uncertainty.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is gaining significant traction following a definitive commercial agreement and strategic investment from TELUS, reinforcing its commercial validation and financial runway. The community is overwhelmingly bullish on the company's strong earnings, projecting substantial revenue growth and accelerating satellite deployment, particularly as it displays remarkable strength amidst a challenging market.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amidst surging crude oil prices driven by escalating Middle East tensions and threats to the Strait of Hormuz, sparking intense community debate as the stock experiences a sharp sell-off. Investors are questioning potential market manipulation or dilution, while others anticipate a significant rebound due to its low float and high short interest.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending as a highly leveraged bet on Bitcoin's price movements, with community sentiment sharply divided. Bulls are actively discussing the potential for a significant short squeeze as MSTR continues its strategy of acquiring more BTC, while bears express concern over ongoing share dilution and the company's valuation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as reports indicate major automakers are exiting its EU carbon credit pool, potentially impacting a revenue stream, while Elon Musk's ambitious push into AI and humanoid robotics sparks intense community debate over the company's future direction amidst broader market volatility.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending sharply upward after its robust Q4 earnings reported significant growth in USDC circulation and profitability, fueling a massive short squeeze. The community is buzzing about its foundational role in AI agentic commerce and its potential to benefit from both favorable stablecoin regulation and persistent interest rate levels.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to its announced strategic partnership with Starwood Capital to develop AI/HPC data centers, a significant pivot from pure Bitcoin mining that is sparking fervent debate among investors. Despite a substantial Q4 net loss driven by Bitcoin write-downs, the community is weighing this diversification as a potential long-term value driver against concerns about execution and market timing.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid high anticipation for its upcoming earnings, as the community fiercely debates its valuation and strategic position in the evolving Agentic AI landscape. Investors are polarized between those highlighting its strong balance sheet, institutional ownership, and role as an AI orchestration platform, and those concerned about competition and recent price weakness, fueling speculation of a potential short squeeze.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending as its dedicated community champions extensive real-world brand building through initiatives like KENDU SPICE and energy drinks, coupled with its verified token presence across Ethereum and Base. Members are actively engaged in dollar-cost averaging and showcasing strong conviction in the project's long-term vision, distinguishing it as a brand-focused entity in the crypto space.

Wix.com Ltd. engages in providing a web development platform for creators, delivering its solutions through a Software-as-a-Service model. Its products include website templates, website builder, website design, Wix features, app market, web hosting, domain names, website accessibility, mobile app builder, and AI website builder. The company was founded by Avishai Abrahami, Nadav Abrahami, Nir Zohar, and Giora Kaplan on October 5, 2006 and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix is trending after a mixed earnings report that saw an EPS beat offset by a revenue miss, fueling community debate. Investors are actively discussing the company's substantial share repurchase program, robust free cash flow, and strategic AI integrations like Base44 and Harmony as potential catalysts, while also weighing concerns about broader AI disruption in the web development space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company announced a 1-for-25 reverse stock split.</li><li>The split takes effect Thursday, with split-adjusted trading Friday, reducing outstanding shares to about 1.1 million from 27.8 million.</li><li>The move comes amid continued progress on AD04, with Phase 3 planning completed.</li></ul>Shares of Adial Pharmaceuticals Inc.&nbsp;cratered over 20% in after-hours trading on Tuesday after the company announced a 1-for-25 reverse stock split to restore compliance with Nasdaq’s minimum bid price requirement.<h2 class="st-heading-2">ADIL Reverse Stock Split&nbsp;</h2>Adial said the reverse split will take effect Thursday, with the stock set to begin trading on a split-adjusted basis on Friday. This will reduce outstanding common shares to nearly 1.1 million from about 27.8 million, while shareholder ownership percentages will remain unchanged, apart from the treatment of fractional shares. The company added that proportional adjustments will be made to outstanding equity awards and warrants, including exercise prices.Adial said the reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule, a requirement for maintaining its listing.<h2 class="st-heading-2">AD04 Development In Focus</h2>The reverse split comes as Adial continues to advance AD04, its genetically targeted serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder, with a focus on heavy drinking patients and select genotypes.The company has advanced Phase 3 trial design and planning, drawing on analyses of historical clinical data that identified genotype-defined subgroups more likely to benefit from the therapy.&nbsp;On the regulatory front, Adial completed its End-of-Phase-2 discussions with the U.S. Food and Drug Administration (FDA), saying the agency provided input on the Phase 3 adaptive trial design and the broader clinical program. The company said the discussions covered key elements such as patient population, endpoints, dosing, and confirmation of biomarker-positive and biomarker-negative groups, including a focus on the AG+ genotype, and were later formalized through final FDA meeting minutes.Adial has also worked to strengthen intellectual property protection for AD04, saying an international patent application covering the program has been published and, if granted, is expected to protect its core assets through at least 2045.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/adil_ss_png_001d17e3e8.webp" alt="adil ss.png" width="975" height="148"><figcaption>ADIL sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user said the market reaction appeared overly short-term focused, adding that near-term share price moves mattered less to them, as they viewed Adial as a “long-term story” and said the company’s underlying clinical progress has been moving well.<stembedurl>https://stocktwits.com/Prazzclatt/message/643712705</stembedurl>Another user said, “more dilution will follow after min price bid met. It will be voted on at end of the month. This will likely be below $1 again by March.”<stembedurl>https://stocktwits.com/StayPresent/message/643885507</stembedurl><a href="https://stocktwits.com/symbol/ADIL">ADIL’s stock</a> has declined 75% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Equity

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Current Price	$2.29
Prev Close	$2.47
Open	$2.46
Dividend Yield	N/A
50-Day Moving Average	$4.71
Beta	0.94
Avg. Volume	69,945.33
PE Ratio	-0.11

52-Week High	$30.25
52-Week Low	$2.27
Market Capitalization	$2.74M
EPS (Annual)	-$68.01
Price to Book	0.52
Revenue Per Employee	$0.00

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADIL News

ADILAdial Pharmaceuticals Inc